NDAORALTABLET
Approved
Oct 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
FYCOMPA (perampanel) by Catalyst Pharmaceuticals is ampa receptor antagonists [moa]. Approved for epilepsy, partial-onset seizures, generalized tonic-clonic seizures and 1 more indications. First approved in 2012.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FYCOMPA (perampanel) is an oral tablet approved in October 2012 as a noncompetitive AMPA glutamate receptor antagonist for the treatment of epilepsy. It represents a distinct mechanism of action within the antiepileptic drug class, targeting glutamate-mediated excitotoxicity rather than GABA potentiation or sodium channel inhibition. The product is positioned as an adjunctive therapy option for patients with partial-onset or generalized seizures who have inadequate control on existing antiepileptic regimens.
$0.1BPart D
2mo to LOEMechanism of Action
AMPA Receptor Antagonists
Pharmacologic Class:
Noncompetitive AMPA Glutamate Receptor Antagonist
Indications (4)
Worked on FYCOMPA at Catalyst Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.